Important Notes

• FS344 "human dosing" in literature = AAV gene transfer dosing (vg/kg).
• If someone is quoting a "mcg/day" or "mg/week" FS344 protocol, that is generally not coming from human clinical trials (and should not be presented as standardized human dosing).
• This is not FDA‑approved as a commercial therapy; use is within controlled research/clinical protocols.

How This Works

Follistatin binds/inhibits myostatin/activin‑family signaling, which can shift muscle growth regulation pathways. Human trials attempt to achieve localized, sustained expression in injected muscles via AAV delivery.

Benefits & Side Effects (Human trial framing)

What trials measured (examples):

• Functional outcomes (e.g., 6‑minute walk test)
• Muscle performance measures
• Safety/tolerability and follow‑up monitoring

Because this is gene transfer, safety considerations are evaluated differently than for short‑acting peptides.

Lifestyle Factors

In at least one human protocol, an exercise regimen was included alongside gene transfer—important when interpreting outcomes.

Injection Technique

For this page, best practice is to avoid "how‑to" injection technique instructions, because human FS344 dosing in the literature is clinical gene therapy delivered by professionals under protocol.

Administration is performed by trained clinical staff; not a self‑administration protocol.

Recommended Source

From an educational/compliance standpoint:

• Reference published clinical trials and ClinicalTrials.gov entries for dosing details.
• Avoid presenting non‑trial dosing as "human protocol."